Novavax Inc (NVAX)

R&D Expenses

$338.42M

TTM · Period ending: · USD

NVAX logo

NVAX R&D Expenses

Latest reported$338.42M
NVAX TTM R&D Expenses ($3.70M → $338.42M)
High-resolution chart · PNG

NVAX r&d expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Novavax Inc R&D Expenses — Trailing twelve months (TTM) (USD)
Period endingR&D Expenses (USD)
338,415,000
345,355,000
338,820,000
369,224,000
358,114,000
387,427,000
391,169,000
451,486,000
470,551,000
583,080,000
737,502,000
830,655,000
1,028,723,000
1,098,896,000
1,235,278,000
1,940,385,000
2,044,283,000
2,325,320,000
2,534,508,000
1,972,750,000
1,858,642,000
1,322,803,000
747,027,000
375,169,000
99,693,000
95,264,000
113,842,000
127,916,000
150,631,000
164,756,000
173,797,000
180,039,000
180,575,000
175,296,000
168,436,000
169,879,000
181,000,000
206,641,000
237,939,000
262,742,000
237,676,000
197,814,000
154,750,000
109,342,000
100,644,000
90,804,000
79,434,000
65,258,000
59,987,000
55,570,000
50,484,000
43,577,000
36,024,000
30,415,000
26,060,000
17,296,000
17,140,000
17,548,000
17,885,000
22,043,000
23,674,000
24,417,000
28,032,000
34,187,000
31,573,000
30,543,000
25,780,000
20,684,000
24,083,000
24,166,000
24,334,000
22,582,000
19,561,000
18,374,000
17,599,000
16,679,000
13,948,000
13,156,000
11,529,000
9,652,000
7,910,000
5,886,000
5,076,000
5,301,000
5,692,000
5,544,000
7,369,000
8,173,000
9,175,000
10,738,000
10,056,000
9,364,000
10,512,000
10,925,000
11,502,000
12,438,000
10,493,000
11,125,000
10,775,000
10,983,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.